{
  "retracted": false,
  "timestamp": 1580428800000,
  "updates": [
    {
      "timestamp": 1591736506669,
      "identifier": {
        "doi": "10.1186/s13058-020-1254-5"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1186/s13058-019-1222-0"
  },
  "journal": "Breast Cancer Research",
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer"
}
